



山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited*
(a joint stock limited company incorporated in the People's Republic of China)
(stock code: 8199)

**RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON 15 DECEMBER 2008 AND
APPOINTMENT OF NON-EXECUTIVE DIRECTORS**

The board (the “**Board**”) of directors (the “**Directors**”) of 山東威高集團醫用高分子製品股份有限公司 (Shandong Weigao Group Medical Polymer Company Limited)* (the “**Company**”) is pleased to announce that the extraordinary general meeting (the “**EGM**”) was held on 15 December 2008. Poll voting was demanded by the Chairman of the EGM in relation to the proposed resolutions as set out in the notice of EGM dated 28 October 2008. 威海啓迪會計師事務所有限公司, (Weihai Qidi Accounting Company Limited)*, certified public accountants in the PRC, was appointed as the scrutineer for the vote-taking of the poll at the EGM. Terms used in the announcement shall adopt the same meaning as stated in the circulars of the Company dated 16 April 2008 and 28 October 2008. All the resolutions were duly passed and the poll results were as follows:

Ordinary Resolutions	For No of Votes (%)	Against No of Votes (%)
1. To approve, subject to the completion of the issuance of the Subscription Shares by the Company, and the sale of the Sale Shares by Weigao Holding and the Management Shareholders, to Medtronic Switzerland, the appointment of Mr. Butel as non-executive director of the Company, with effect upon the completion date of the SPA (as amended, modified and supplemented by the Supplemental Deed) and to authorize a Director to execute all documents or do such lawful acts and things as deemed necessary or desirable for the purpose of giving effect to such appointment.	192,317,098 H Shares 89.6%	22,229,755 H Shares 10.4%

Ordinary Resolutions	For No of Votes (%)	Against No of Votes (%)
2. To approve, subject to the completion of the issuance of the Subscription Shares by the Company, and the sale of the Sale Shares by Weigao Holding and the Management Shareholders, to Medtronic Switzerland, the appointment of Mr. Li as non-executive director of the Company, with effect upon the completion date of the SPA (as amended, modified and supplemented by the Supplemental Deed) and to authorize a Director to execute all documents or do such lawful acts and things as deemed necessary or desirable for the purpose of giving effect to such appointment.	161,092,003 H Shares 75.1%	53,454,850 H Shares 24.9%

As at the date of the EGM, the total number of issued shares of the Company entitling the holders to attend and vote for or against the ordinary resolutions at the EGM is 347,400,000 H Shares. There are no shares of the Company entitling the holder to attend and vote against the ordinary resolutions at the EGM.

The resolutions require the approval of the Independent Shareholders, Weigao Holding and Management Shareholders shall abstain and had abstained from voting the ordinary resolutions at the EGM.

APPOINTMENT OF NON-EXECUTIVE DIRECTORS

With regard to resolutions (1) and (2) duly passed at the EGM, the Board hereby announces that the appointment of Mr. Butel and Mr. Li will take effect upon completion date of the Subscription Deed and the Share Transfer Deed, which shall take place on the fifth (5th) business day from and excluding the date on which the last of the conditions set forth in the Subscription Deed and the Share Transfer Deed have been fulfilled or waived (as the case may be) or such other date as the parties thereto may agree. Details of the new non-executive Directors are set out as follows:

Mr. Butel, age 51, is senior vice president of Medtronic and the President of Medtronic International Limited. Mr. Butel is responsible for all of Medtronic's operations outside of the United States. Prior to holding his current position, Mr. Butel served as President of Medtronic in Asia Pacific and he was responsible for managing and driving all business activities for Medtronic in the Asia Pacific region.

Prior to joining Medtronic, he was the president of Independence Technology, a Johnson & Johnson company, where he focused on providing mobility systems for the movement impaired. From 1991 to 1999, he worked for Becton Dickinson, initially as the general manager of its microbiology business in Japan and then as President of Nippon Becton Dickinson. From 1985 to 1991, Mr. Butel was with Johnson & Johnson and served multiple roles including general manager of Fiji, China project manager and marketing director of Johnson & Johnson's ophthalmic business in Southeast Asia.

Mr. Butel has a bachelor degree in International Affairs from George Washington University and a master degree in Business and Administration from American Graduate School of International Management (Thunderbird).

Mr. Li, age 58, is and has been President of Medtronic's operations in the greater China region since February 2007. Prior to his current position, Mr. Li served as vice president of the commercial operations section of several Medtronic's operations in the greater China region. Mr. Li has extensive experience in management in the Asia Pacific region. From 1996 to 2005, Mr. Li was with Johnson & Johnson Medical (China) Co. Ltd. where he held a number of executive positions and he was subsequently promoted to International Vice President in North Asia.

Prior to joining Johnson & Johnson in 1996, Mr. Li was the managing director in Asia Pacific for the ConvaTec Division of Bristol Myers Squibb for 9 years.

Mr. Li graduated with a bachelor degree in Social Sciences from the University of Hong Kong in 1976 and obtained a masters degree in Business Administration from Henley Management School of the United Kingdom in 1989.

There is no service contract entered into between the Company and Mr. Butel and Mr. Li, respectively. Neither Mr. Butel nor Mr. Li will receive any remuneration arising from their appointments as Directors. Mr. Li has been appointed as a director of the Distribution JV.

Save as disclosed herein, as at the date of this announcement, neither Mr. Butel nor Mr. Li:-

- (a) holds any other positions with the Company or any other members of the Group;
- (b) has any relationship with any directors, senior management, management shareholders, substantial shareholders, or controlling shareholders of the Company;

- (c) holds any directorships in other listed public companies in the last three years; and
- (d) has any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Other than the matters disclosed herein, there are no other matters concerning Mr. Butel and Mr. Li that are required to be brought to the attention of the Shareholders pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules. The Board takes this opportunity to express its warm welcome to Mr. Butel and Mr. Li and thank Mr. Butel and Mr. Li for their contributions to the Company.

By order of the Board
**Shandong Weigao Group Medical
Polymer Company Limited**
Chen Xue Li
Chairman

Weihai, Shandong, the PRC
15 December 2008

As at the date of this announcement, the Board comprises:

Mr. Zhang Hua Wei (*Executive Director*)
Mr. Miao Yan Guo (*Executive Director*)
Mr. Wang Yi (*Executive Director*)
Mr. Wang Zhi Fan (*Executive Director*)
Mr. Wu Chuan Ming (*Executive Director*)
Mr. Chen Xue Li (*Non-executive Director*)
Mrs. Zhou Shu Hua (*Non-executive Director*)
Mr. Shi Huan (*Independent non-executive Director*)
Mr. Luan Jian Ping (*Independent non-executive Director*)
Mr. Lau Wai Kit (*Independent non-executive Director*)
Mr. Li Jia Miao (*Independent non-executive Director*)

This announcement will remain on the GEM website at <http://www.hkgem.com> on the "Latest Company Announcement" page for at least seven days from the date of its posting.

* *For identification purposes only*